Heidelberg Pharma AG annual gross margin
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Heidelberg Pharma AG Gross Margin Growth & History (HPHA)
Heidelberg Pharma AG's gross margin was 81.51% for fiscal 2025.
View full Heidelberg Pharma AG company overviewHeidelberg Pharma AG annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-11-30 | 81.51% | +7.49 pp |
| 2024 | 2024-11-30 | 74.01% | +6.98 pp |
| 2023 | 2023-11-30 | 67.04% | −7.68 pp |
| 2022 | 2022-11-30 | 74.72% | +243.86 pp |
| 2021 | 2021-11-30 | −169.14% | −203.18 pp |
| 2020 | 2020-11-30 | 34.04% | −14.80 pp |
| 2019 | 2019-11-30 | 48.84% | +9.06 pp |
| 2018 | 2018-11-30 | 39.78% | −9.69 pp |
| 2017 | 2017-11-30 | 49.47% | +9.03 pp |
| 2016 | 2016-11-30 | 40.44% | −9.56 pp |
| 2015 | 2015-11-30 | 50.00% | −12.22 pp |
| 2014 | 2014-11-30 | 62.22% | −10.15 pp |
| 2013 | 2013-11-30 | 72.37% | +14.13 pp |
| 2012 | 2012-11-30 | 58.24% | +0.45 pp |
| 2011 | 2011-11-30 | 57.79% | — |
Heidelberg Pharma AG gross margin trends
Over the last five fiscal years, Heidelberg Pharma AG's gross margin increased from 34.04% to 81.51%, a change of +47.47 percentage points.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as reported gross profit divided by reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Heidelberg Pharma AG source filings ↗Community posts
Heidelberg Pharma reports early myeloma responses and selects a development dose
Heidelberg Pharma ($HPHA) presented Phase 1 results for pamlectabart tismanitin, its experimental antibody-drug conjugate for relapsed or refractory multiple myeloma. Among 31 evaluable patients in dose cohorts five through nine, 13 respond ...
